登录 | 注册    关注公众号  
微信公众号
搜索
 > 【M-CSF】

M-CSF信息

英文名称:Macrophage Colony Stimulating Factor 1
中文名称:巨噬细胞集落刺激因子-1
靶点别称:M-CSF,Macrophage colony-stimulating factor 1,CSF-1,CSF1,Colony Stimulating Factor 1,Colony Stimulating Factor 1 (Macrophage),Macrophage Colony Stimulating Factor 1,Lanimostim,MCSF,Macrophage Colony-Stimulating Factor,MGC31930
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

M-CSF产品列表

ACRO质量管理体系
 
评论(9)
MCF-H5247|Human M-CSF / CSF-1 Protein, His Tag
  1. 156XXXXXXX8
  2. 5人赞
  3. M-CSF用于开展巨噬细胞的诱导实验,添加M-CSF蛋白诱导PBMC成巨噬细胞,用于开展巨噬细胞的吞噬作用的评价实验。
  4. 2021-08-19
MCF-H5218|Human M-CSF / CSF-1 Protein, premium grade
  1. 188XXXXXXX9
  2. 2人赞
  3. 下单后,抗原很快就到了,而且包装完整,标签清晰。 从验证数据来看,精密度和重复性良好,且比较稳定。 -80度以下保存和溶解后-20度以下保存均稳定.
  4. 2023-09-26
MCF-H5218|Human M-CSF / CSF-1 Protein, premium grade
  1. 188XXXXXXX9
  2. 0人赞
  3. After placing the order, the antigen arrived very quickly, and the package was complete and the label was clear. Judging from the verification data, the precision and repeatability were good, and it was relatively stable. The preservation below -80 degrees and the preservation below -20 degrees after dissolution were both stable
  4. 2023-06-02
 

M-CSF分子别名

M-CSF,CSF-1,Lanimostim

M-CSF分子背景

The colony stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor (M-CSF), is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. Eukaryotic cells also produce M-CSF in order to combat intercellular viral infection. It is one of the three experimentally described colony-stimulating factors. M-CSF binds to the colony stimulating factor 1 receptor. Macrophage colony-stimulating factor has been shown to interact with PIK3R2. M-CSF (or CSF-1) is a hematopoietic growth factor that is involved in the proliferation, differentiation, and survival of monocytes, macrophages, and bone marrow progenitor cells. Locally produced M-CSF in the vessel wall contributes to the development and progression of atherosclerosis.

M-CSF临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Lacnotuzumab MCS-110 临床二期 诺华制药 骨转移, 腱鞘巨细胞瘤, 胃癌, 色素沉着绒毛结节性滑膜炎, 三阴性乳腺癌, 胰腺癌, 前列腺癌, 乳腺癌, 巨细胞瘤, 子宫内膜癌, 黑色素瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定